** Shares of New Jersey-based drug distributor Wellgistics Health WGRX.O rise 9.3% to $2.95 premarket
** Company announces it is collaborating with Protega Pharmaceuticals to increase patient access to Protega's opioid, Roxybond
** Roxybond is indicated for managing severe pain when other treatments are insufficient
** WGRX has fallen 29% since its debut on February 21
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。